COVID-19 infection has been linked to a range of lasting neurological and psychological disorders, including depression, memory problems, and Parkinson's-like disorders, within the first year following infection.
Targeting the GAT3 protein in the thalamus could help block and prevent long-term damage following brain injury.
Neuroimaging technology allowed researchers to capture the activity of microglia and astrocytes in the brain. The researchers were able to quantify alterations in the morphology of different cell populations implicated in neuroinflammation.
Administering a lipid that mediates inflammation reduced chronic inflammation associated with multiple sclerosis in mouse models. Researchers found these mediator lipids are reduced in humans with multiple sclerosis.
Immune system mediated injury rather than the virus entering and killing brain cells may explain why people experience long-term consequences associated with COVID-19 infection.
New findings reveal phagocytes do not fully mature until after birth, contradicting previous assumptions that they mature during embryonic development.
An abundance of newly acquired mutations in the mutations that occur at an accelerated speed is a telling pattern of Alzheimer's disease, researchers report.
The activation of a neural circuit comprising of the central nucleus of the amygdala and the bed nucleus of the stria terminalis in the first hours following sepsis infection induced anxiety behaviors in mice two weeks after the infection cleared. The behaviors mimicked the PTSD symptoms patients experience following sepsis infection.
Daily vaping of pod-based e-cigarettes alters inflammatory states across multiple organs, including the brain. The effects vary depending upon the vape flavors and influence how the body responds to infections. Mint vapes, for example, leave people more sensitive to the effects of bacterial pneumonia than mango flavoring.
Genes associated with inflammation were linked to reduced gray matter in brain areas associated with neuropsychiatric disorders. The findings shed new light on how neurodevelopmental psychiatric disorders such as schizophrenia and ASD may occur.
GM-CSF/sargramostim, a drug that improved memory in Alzheimer's patients during a phase II clinical trial, also appears to improve cognitive function in older adults and those with Down syndrome.
Intranasal delivery of biologically active lipid messengers halts memory loss and neurodegeneration in mouse models of Alzheimer's disease.
